Dear Editor;

Viral hepatitis represents a major cause of chronic liver disease leading to cirrhosis and hepatocellular carcinoma (HCC), worldwide. Increased iron storage has an important role in the diseases associated with Hepatitis B virus (HBV). This may be associated with the iron’s ability to produce oxidative stress and cause tissue damage and chronic inflammation in the liver. Hepcidin is a hormone which functions as a key regulator in iron homeostasis and is produced in the liver. Understanding the regulation of hepcidin in chronic viral hepatitis (CVD) associated diseases may explain the relation among viral hepatitis, iron accumulation and HCC to a great extent (1,2). In this study, serum prohepcidin levels were assessed in four different groups of patients followed up with the diagnosis of chronic hepatitis B (CHB). The aim of this study was to evaluate prohepcidin levels with HBV-DNA levels in HBV infected patients and healthy volunteers.

The study included the serum samples, which were sent to Sakarya University, Sakarya Training and Research Hospital, Medical Microbiology Laboratory and routinely tested and then stored at -80 °C, from patients who were followed up with CHB infection and healthy population. Patients with chronic hepatic or hematologic conditions were excluded. The participants were divided into four groups according to their status of using medication and level of viral load (≥10^5 IU/mL was accepted as high). The serum prohepcidin levels in the samples of the study were investigated with the method of ELISA test (Boster, Pleasanton CA).

A total of 60 patients with CHB (33 male, mean age 42.4±6.3 years) and 20 healthy volunteers were included in the study. The prohepcidin levels of the control group were found to be higher than patient groups. Also, it was detected to be higher in those with the viral load <10^5 IU/mL compared to those with the viral load ≥10^5 IU/mL. The prohepcidin levels of the control group and patient groups are illustrated in the Table 1.

Hepcidin is a circulating peptide hormone that is synthesized mainly from the liver and is the main regulator of systemic iron balance. As it is produced mainly by hepatocytes, liver diseases may affect hepcidin production. There are a few studies evaluating hepcidin expression in CVD but remains controversial. Understanding the regulation of hepcidin in HBV-associated diseases may increase our knowledge on the relationship among

viral hepatitis, iron storage and HCC. Although the determination of hepcidin levels by immunoassays and mass spectrometry has begun to be used more, accurate and easy hepcidin quantitation remains as a problem.

The elevated serum iron level has been described in chronic liver diseases, including CHC, nonalcoholic steatohepatitis and alcoholic liver disease (3,4). However, some other studies show that hepcidin was down-regulated in HCV and liver cirrhosis, and ferritin levels being negatively correlated (5). There are few reports of hepcidin levels in patients with HBV infections, and the results are inconsistent. Wang et al. (2) showed that serum ferritin and hepcidin levels were significantly higher in patients with hepatitis B than in controls, and positive correlations were found between log (hepcidin) and log (HBV-DNA) (2). However, Armitage et al. (4) found that there was no evidence of hepcidin up-regulation during the primary viremia phases of HCV or HBV infection.

We found that prohepcidin levels are significantly lower in patients with CHB, in our study. Since our study had cross-sectional design, the prognostic value of low prohepcidin in chronic HBV could not be assessed. There is still need for further research on physiological and pathological changes of hepcidin during HBV infection for better understanding clinical monitoring and management of HBV-associated diseases.

**Ethics**

**Peer-review:**

**Authorship Contributions**


**Conflict of Interest:** No conflict of interest was declared by the authors.

**Financial Disclosure:** The authors declared that this study has received no financial support.

**References**


### Table 1. Prohepcidin levels of the patient groups and control group

<table>
<thead>
<tr>
<th>Prohepcidin-level (pg/mL)</th>
<th>Patients on medication and with HBV-DNA &lt;10⁵ IU/mL, (n=15)</th>
<th>Patients on medication and with HBV-DNA &gt;10⁵ IU/mL, (n=15)</th>
<th>Patients who were not on medication and with HBV-DNA &lt;10⁵ IU/mL, (n=15)</th>
<th>Patients who were not on medication and with HBV-DNA &gt;10⁵ IU/mL, (n=15)</th>
<th>Control group, (n=20)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Minimum</td>
<td>133</td>
<td>131</td>
<td>70</td>
<td>216</td>
<td>629</td>
</tr>
<tr>
<td>Maximum</td>
<td>1272</td>
<td>851</td>
<td>1132</td>
<td>1117</td>
<td>1819</td>
</tr>
<tr>
<td>Mean value</td>
<td>644.06</td>
<td>619.57</td>
<td>742.88</td>
<td>695.55</td>
<td>1185.1</td>
</tr>
</tbody>
</table>

P<0.05 between group 1 and 2, p>0.05 between group 3 and 4, p<0.05 between control group and all patient groups.

HBV: Hepatitis B virus,